Kadmon Holdings Inc. (NYSE:KDMN) and Emergent BioSolutions Inc. (NYSE:EBS) compete with each other in the Biotechnology sector. We will analyze and contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kadmon Holdings Inc.	2.63M	94.28	32.91M	-0.41	0.00
Emergent BioSolutions Inc.	705.48M	4.64	100.12M	1.96	34.24

Demonstrates Kadmon Holdings Inc. and Emergent BioSolutions Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Kadmon Holdings Inc.	-1,251.33%	-116.9%	-25.7%
Emergent BioSolutions Inc.	14.19%	10.8%	9%

Liquidity

6.6 and 6.6 are the respective Current Ratio and a Quick Ratio of Kadmon Holdings Inc. Its rival Emergent BioSolutions Inc.’s Current and Quick Ratios are 5.5 and 4.3 respectively. Kadmon Holdings Inc. has a better chance of clearing its pay short and long-term debts than Emergent BioSolutions Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Kadmon Holdings Inc. and Emergent BioSolutions Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Kadmon Holdings Inc.	0	0	0	0.00
Emergent BioSolutions Inc.	0	1	3	2.75

Competitively the consensus price target of Emergent BioSolutions Inc. is $70.25, which is potential 9.29% upside.

Institutional and Insider Ownership

Roughly 71.8% of Kadmon Holdings Inc. shares are owned by institutional investors while 84.2% of Emergent BioSolutions Inc. are owned by institutional investors. 0.49% are Kadmon Holdings Inc.’s share owned by insiders. Competitively, insiders own roughly 3.5% of Emergent BioSolutions Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Kadmon Holdings Inc.	-0.41%	-10.33%	-33.24%	-27.46%	-30.77%	-32.87%
Emergent BioSolutions Inc.	-8.02%	-3.69%	13.5%	26.97%	57.94%	44.18%

For the past year Kadmon Holdings Inc. has -32.87% weaker performance while Emergent BioSolutions Inc. has 44.18% stronger performance.

Summary

Emergent BioSolutions Inc. beats Kadmon Holdings Inc. on 10 of the 12 factors.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. Its lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of WilsonÂ’s disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; VIVUS, Inc.; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.